Aller au contenu
GLP-1 Newspaper: Daily Ozempic, Zepbound & Weight-Loss Drug News

GLP-1 Newspaper: Daily Ozempic, Zepbound & Weight-Loss Drug News

NouveauNovo's CagriSema Cut Weight About 21% at Two Lower Doses in Phase 3 REDEFINE 9 Trial15 novembre 2026 · 7 min
Épisodes
17
Parution
quotidienne
Dernier épisode
15 Nov 2026

À propos du podcast

One GLP-1 story a day, sourced and explained. GLP-1 Newspaper covers the biggest daily news on weight-loss and diabetes drugs like Ozempic, Wegovy, Zepbound, Mounjaro, and new ones like retatrutide, orforglipron, and the Wegovy pill. Each short episode breaks down one story, such as an FDA decision, new trial results, price and insurance changes, shortages, or safety updates. We cover what happened, what it means for patients, and what we don't know yet. Every episode links to its primary sources, like FDA notices, clinical trial records, journals, and company announcements, at glp1newspaper.com.

For information only, not medical advice. Always talk to your doctor before starting, stopping, or changing any medication.

Licence : © 2026 GLP-1 Newspaper. All rights reserved.

Épisodes 17

  1. Novo's CagriSema Cut Weight About 21% at Two Lower Doses in Phase 3 REDEFINE 9 Trial

    7 min

    Novo Nordisk reported full results from REDEFINE 9, the first Phase 3 weight-management trial of its investigational once-weekly injection CagriSema (a fixed-dose combination of the amylin analog cagrilintide …

  2. China Approves Lilly's Orforglipron Pill for Weight Management, the First Oral GLP-1 Cleared There for That Use

    3 min

    China's National Medical Products Administration has approved Eli Lilly's once-daily oral GLP-1 pill orforglipron, sold as Foundayo in the US and UK and as Muyouda in China, for long-term weight management …

  3. CDC Survey: About 1 in 10 U.S. Adults Used a GLP-1 in 2025, and 44% of Users Changed How They Took It

    5 min

    A new CDC report published November 12, 2026, in the Morbidity and Mortality Weekly Report looks at how U.S. adults used GLP-1 medications in 2025. In a national survey of 8,118 adults through CDC's Rapid …

  4. Boehringer's Survodutide Did Not Raise Heart Risk in a 5,530-Person Phase 3 Safety Trial, as Boehringer Moves Toward Obesity Filings

    5 min

    Boehringer Ingelheim's investigational weekly injection survodutide, a glucagon/GLP-1 dual agonist, did not increase the risk of major heart and blood-vessel events compared with placebo in the Phase 3 …

  5. Lilly's Foundayo Pill Reduced Sleep Apnea Severity in Two Phase 3 Trials, With an FDA Filing Planned by Year-End

    6 min

    Eli Lilly's once-daily GLP-1 pill Foundayo (orforglipron) reduced the severity of obstructive sleep apnea in its Phase 3 ATTAIN-OSA program, presented at the American Heart Association's Scientific Sessions …

  6. FDA Requires a Warning About Rare Vision Loss (NAION) on All GLP-1 Drugs, From Ozempic and Wegovy to Mounjaro and Zepbound

    7 min

    On November 9, 2026, the US Food and Drug Administration said it is requiring the makers of all GLP-1 receptor agonist medicines, including Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound and Foundayo, to add …

  7. Semaglutide Lowered Heart Filling Pressures in a Small Obesity-Related Heart Failure Trial, Plus New Tirzepatide MRI Data From SUMMIT

    7 min

    Two new sets of heart-failure data on GLP-1-based drugs were presented at the American Heart Association's Scientific Sessions 2026 in Chicago on November 8, 2026. In CAMEO-SEMA, a Mayo Clinic-led, double-blind …

  8. Novo Real-World Studies Link Wegovy to Lower Liver Enzymes and Weight in MASH, Presented at The Liver Meeting 2026

    9 min

    Novo Nordisk presented two real-world studies of Wegovy (semaglutide 2.4 mg) in adults with MASH at The Liver Meeting 2026 (AASLD) in Denver on November 6, 2026. In PLATINUM-Truveta, 2,873 adults who started …

  9. Lilly and Hims & Hers Offer Zepbound and Foundayo at Self-Pay Prices Starting at $149 and $299

    10 min

    Eli Lilly and Hims & Hers announced an agreement on November 6, 2026, to expand access to FDA-approved Zepbound (tirzepatide) and Foundayo (orforglipron) through the Hims & Hers telehealth platform. Eligible …

  10. Lilly Oral Orforglipron Beat Placebo on Weight Loss in Japan ATTAIN-J Phase 3, With 12 mg Leading Numerically

    18 min

    Eli Lilly's once-daily oral GLP-1 drug orforglipron reduced body weight more than placebo at 72 weeks in ATTAIN-J, a Japan-only Phase 3 trial in adults with obesity disease. Mean weight change was −5.9% at 6 …

  11. Lilly's Retatrutide Beat Ozempic 2 mg on Blood Sugar and Weight Loss in Head-to-Head Diabetes Trial

    16 min

    Eli Lilly says its investigational once-weekly drug retatrutide beat Novo Nordisk's Ozempic 2 mg in TRANSCEND-T2D-2, the first Phase 3 trial comparing retatrutide head-to-head with another incretin medicine. We …

  12. Lilly Registers Two Phase 3 Trials of EloraTZP, Its Eloralintide-Tirzepatide Combination

    6 min

    Eli Lilly has registered two phase 3 trials of EloraTZP, an investigational once-weekly combination of the amylin agonist eloralintide and tirzepatide (the active ingredient in Zepbound and Mounjaro), on …

  13. Lilly's Retatrutide Eased Sleep Apnea in Two Phase 3 Trials, NEJM Study Reports

    13 min

    Two phase 3 trials published in the New England Journal of Medicine found that Eli Lilly's investigational drug retatrutide, a once-weekly injection that acts on GIP, GLP-1 and glucagon receptors, reduced the …

  14. ACOG Issues New Guidance on GLP-1 Drugs Before Pregnancy, During Pregnancy and While Breastfeeding

    9 min

    The American College of Obstetricians and Gynecologists (ACOG) released new guidance on October 23, 2026, on GLP-1 medications before, during and after pregnancy. The Practice Advisory tells ob-gyns to advise …

  15. Compounded GLP-1 Recall and 'Research Use' Retatrutide Put Unapproved Weight-Loss Drugs Under Scrutiny

    22 min

    Unapproved GLP-1 drugs are under pressure from several directions. Compounding pharmacy Apothecary Pharma voluntarily recalled 22 lots of compounded tirzepatide, the active ingredient in Zepbound and Mounjaro …

  16. EU Regulators Back Lilly's Foundayo Pill for Weight Loss and Type 2 Diabetes

    11 min

    Europe's drug regulator has recommended approval of Eli Lilly's once-daily GLP-1 pill Foundayo (orforglipron) for adults, covering both weight management and type 2 diabetes. The European Medicines Agency's …

  17. Novo Says Women Lost 25% on CagriSema in Trial Analysis, With Differences by Menopause Stage

    15 min

    Novo Nordisk says women in its phase 3 REDEFINE 1 trial lost 25.0% of their body weight on average after 68 weeks on its investigational weekly injection CagriSema (cagrilintide plus semaglutide), compared with …

C’est votre podcast ?

Confirmez-le avec une entrée dans votre flux : vous recevez ici un code, vous l’ajoutez comme podcast:txt dans le canal de votre flux, et nous le vérifions. Votre podcast apparaît ensuite comme « vérifié » sur SoundNode.

Paramètres

Affichage

Langue

Détermine les stations affichées en premier sur la page d’accueil.

Historique

Les stations et épisodes écoutés récemment et tes dernières recherches sont seulement enregistrés dans ce navigateur.

Notifications

Un court message quand un podcast que tu suis publie un nouvel épisode. Désactive un podcast précis avec la cloche sur sa page.

Compte

Enregistrez vos favoris – dans l’app et sur le site.

Raccourcis clavier

/
Ouvrir la recherche
Espace
Lecture ou pause
← →
Dans le lecteur : 15 s en arrière, 30 s en avant (épisodes) · dans une rangée : tuile suivante
↑ ↓
Dans une rangée : cible dans la tuile
Début / Fin
Dans une rangée : première ou dernière tuile
Esc
Fermer la fenêtre ou le menu
?
Cet aperçu
En cours de lecture

Voir la station

À suivre

    Ajoutez des épisodes avec « À suivre » – ils seront lus après l'épisode en cours.